Parvovirus B19 Infection in Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 36, Issue 12, 2014, Pages 1107-1116

  Crane, Joan ^a   Mundle, William ^a   Boucoiran, Isabelle ^a   Gagnon, Robert ^a   Bujold, Emmanuel ^a   Basso, Melanie ^a   Bos, Hayley ^a   Brown, Richard ^a   Cooper, Stephanie ^a   Gouin, Katy ^a   McLeod, N Lynne ^a   Menticoglou, Savas ^a   Pylypjuk, Christy ^a   Roggensack, Anne ^a   Sanderson, Frank ^a  

^a NONE   (Canada)

Author keywords

Hydrops; Infection; Parvovirus; Pregnancy

Indexed keywords

CORTICOSTEROID;

ANEMIA; APLASTIC CRISIS; ARTHROPATHY; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD TRANSFUSION; CLINICAL FEATURE; CONGENITAL MALFORMATION; DIFFERENTIAL DIAGNOSIS; ERYTHEMA INFECTIOSUM; FETUS HYDROPS; FETUS OUTCOME; HUMAN; IMMUNOCOMPROMISED PATIENT; INTRAUTERINE INFECTION; MEDICAL LITERATURE; MYOCARDITIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SPONTANEOUS ABORTION;

EID: 84975029682     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30390-X     Document Type: Article

References (87)

1. Levy R., Weissman A., Blomberg G., Hagay Z.J. Infection by parvovirus B19 during pregnancy: a review. Obstet Gynecol Surv 1997, 52:254-259.
2. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet 1975, 1:72-73.
3. Anderson M.J., Jones S.E., Fisher-Hoch S.P., Lewis E., Hall S.M., Bartlett C.L., et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet 1983, 1:1378.
4. Brown T., Anand A., Ritchie L.D., Clewley J.P., Reid T.M. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984, 2:1033-1034.
5. Knott P.D., Welply G.A., Anderson M.J. Serologically proved intrauterine infection with parvovirus. Br Med J (Clin Res Ed) 1984, 289:1660.
6. Kinney J.S., Anderson L.J., Farrar J., Strikas R.A., Kumar M.L., Kliegman R.M., et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988, 157:663-667.
7. Rodis J.F., Hovick T.J., Quinn D.L., Rosengren S.S., Tattersall P. Human parvovirus infection in pregnancy. Obstet Gynecol 1988, 72:733-738.
8. Adler S., Koch W.C. Human parvovirus B19. Infectious diseases of the fetus and newborn infant 2010, 845. Saunders, Philadelphia, 5. 7th ed. J.S. Remington, J.O. Klein (Eds.).
9. Rodis J.F. Parvovirus infection. Clin Obstet Gynecol 1999, 42:107-120. quiz 174-5.
10. de Jong E.P., Walther F.J., Kroes A.C., Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn 2011, 31:419-425. 10.1002/pd.2714.
11. Dijkmans A.C., de Jong E.P., Dijkmans B.A., Lopriore E., Vossen A., Walther F.J., et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr Opin Obstet Gynecol 2012, 24:95-101. 10.1097/GCO.0b013e3283505a9d.
12. Harger J.H., Adler S.P., Koch W.C., Harger G.F. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998, 91:413-420.
13. Anderson L.J. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987, 6:711-718.
14. Markenson G.R., Yancey M.K. Parvovirus B19 infections in pregnancy. Semin Perinatol 1998, 22:309-317.
15. Cohen B.J., Courouce A.M., Schwarz T.F., Okochi K., Kurtzman G.J. Laboratory infection with parvovirus B19. J Clin Pathol 1988, 41:1027-1028.
16. Valeur-Jensen A.K., Pedersen C.B., Westergaard T., Jensen I.P., Lebech M., Andersen P.K., et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999, 281:1099-1105.
17. Röhrer C.I., Gärtner B., Sauerbrei A., Böhm S., Hottenträger B., Raab U., et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008, 136:1564-1575. 10.1017/S0950268807009958.
18. Lamont R.F., Sobel J.D., Vaisbuch E., Kusanovic J.P., Mazaki-Tovi S., Kim S.K., et al. Parvovirus B19 infection in human pregnancy. BJOG 2011, 118:175-186. 10.1111/j.1471-0528.2010.02749.x.
19. Centers for Disease Control (CDC) Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989, 38:81-88. 93-7.
20. Gillespie S.M., Cartter M.L., Asch S., Rokos J.B., Gary G.W., Tsou C.J., et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990, 263:2061-2065.
21. Chorba T., Coccia P., Holman R.C., Tattersall P., Anderson L.J., Sudman J., et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986, 154:383. 383.
22. Plummer F.A., Hammond G.W., Forward K., Sekla L., Thompson L.M., Jones S.E., et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med 1985, 313:74-79. 10.1056/NEJM198507113130203.
23. Chisaka H., Ito K., Niikura H., Sugawara J., Takano T., Murakami T., et al. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med 2006, 209:277-283.
24. White D.G., Woolf A.D., Mortimer P.P., Cohen B.J., Blake D.R., Bacon P.A. Human parvovirus arthropathy. Lancet 1985, 1:419-421.
25. Reid D.M., Reid T.M., Brown T., Rennie J.A., Eastmond C.J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985, 1:422-425.
26. Schwarz T.F., Roggendorf M., Hottenträger B., Deinhardt F., Enders G., Gloning K.P., et al. Human parvovirus B19 infection in pregnancy. Lancet 1988, 2:566-567.
27. Alger L.S. Toxoplasmosis and parvovirus B19. Infect Dis Clin North Am 1997, 11:55-75.
28. Kelleher J.F., Luban N.L., Cohen B.J., Mortimer P.P. Human serum parvovirus as the cause of aplastic crisis in sickle cell disease. Am J Dis Child 1984, 138:401-403.
29. Blacklock H.A., Mortimer P.P. Aplastic crisis and other effects of the human parvovirus infection. Clin Haematol 1984, 13:679-691.
30. Serjeant G.R., Topley J.M., Mason K., Serjeant B.E., Pattison J.R., Jones S.E., et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981, 2:595-597.
31. Young N. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988, 25:159-172.
32. Kurtzman G.J., Ozawa K., Cohen B., Hanson G., Oseas R., Young N.S. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987, 317:287-294. 10.1056/NEJM198707303170506.
33. Kurtzman G.J., Cohen B., Meyers P., Amunullah A., Young N.S. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988, 2:1159-1162.
34. Coulombel L., Morinet F., Mielot F., Tchernia G. Parvovirus infection, leukemia, and immunodeficiency. Lancet 1989, 101. [letter].
35. Koch W.C., Massey G., Russell C.E., Adler S.P. Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. J Pediatr 1990, 116:355-359.
36. Saint-Martin J., Choulot J.J., Bonnaud E., Morinet F. Myocarditis caused by parvovirus. J Pediatr 1990, 116:1007-1008.
37. Malm C., Fridell E., Jansson K. Heart failure after parvovirus B19 infection. Lancet. 1993, 341:1408-1409.
38. Public Health Laboratory Service Working Party on Fifth Disease Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 1990, 300:1166-1170.
39. Gratacós E., Torres P.J., Vidal J., Antolín E., Costa J., Jiménez de Anta M.T., et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis 1995, 171:1360-1363.
40. Leduc L., SOGC Maternal-Fetal Medicine Committee Stillbirth and bereavement: guidelines for stillbirth investigation. SOGC Clinical Practice Guidelines, No. 178, June 2006. J Obstet Gynaecol Can 2006, 28:540-552.
41. Watt A.P., Brown M., Pathiraja M., Anbazhagan A., Coyle P.V. The lack of routine surveillance of parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by occupational exposure. J Med Microbiol 2013, 62(Pt 1):86-92. 10.1099/jmm.0.046714-0. 10.1099/jmm.0.046714-0.
42. Miller E., Fairley C.K., Cohen B.J., Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998, 105:174-178.
43. Rodis J.F., Quinn D.L., Gary G.W., Anderson L.J., Rosengren S., Cartter M.L., et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990, 163(4 Pt 1):1168-1171.
44. Guidozzi F., Ballot D., Rothberg A.D. Human B19 parvovirus infection in an obstetric population. A prospective study determining fetal outcome. J Reprod Med 1994, 39:36-38.
45. Koch W.C., Adler S.P., Harger J. Intrauterine parvovirus B19 infection may cause an asymptomatic or recurrent postnatal infection. Pediatr Infect Dis J 1993, 12:747-750.
46. Koch W.C., Harger J.H., Barnstein B., Adler S.P. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J 1998, 17:489-494.
47. Rodis J.F., Rodner C., Hansen A.A., Borgida A.F., Deoliveira I., Shulman Rosengren S. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol 1998, 91:125-128.
48. Simms R.A., Liebling R.E., Patel R.R., Denbow M.L., Abdel-Fattah S.A., Soothill P.W., et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther 2009, 25:373-378. 10.1159/000236149.
49. Enders M., Schalasta G., Baisch C., Weidner A., Pukkila L., Kaikkonen L., et al. Human parvovirus B19 infection during pregnancy-value of modern molecular and serological diagnostics. J Clin Virol 2006, 35:400-406. 10.1016/j.jcv.2005.11.002.
50. Weiland H.T., Vermey-Keers C., Salimans M.M., Fleuren G.J., Verwey R.A., Anderson M.J. Parvovirus B19 associated with fetal abnormality. Lancet 1987, 1:682-683.
51. Katz V.L., McCoy M.C., Kuller J.A., Hansen W.F. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol. 1996, 13:43-45. 10.1055/s-2007-994201.
52. Barton L.L., Lax D., Shehab Z.M., Keith J.C. Congenital cardiomyopathy associated with human parvovirus B19 infection. Am Heart J 1997, 133:131-133.
53. Tiessen R.G., van Elsacker-Niele A.M., Vermeij-Keers C., Oepkes D., van Roosmalen J., Gorsira M.C. A fetus with a parvovirus B19 infection and congenital anomalies. Prenat Diagn. 1994, 14:173-176.
54. Rodis J.F., Borgida A.F., Wilson M., Egan J.F., Leo M.V., Odibo A.O., et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol 1998, 179:985-988.
55. Enders M., Weidner A., Zoellner I., Searle K., Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004, 24:513-518. 10.1002/pd.940.
56. Desilets V. Audibert F; SOGC Genetics Committee. Investigation and management of non-immune fetal hydrops. SOCG Clinical Practice Guidelines, No. 297, October 2013. J Obstet Gynaecol Can 2013, 35:923-938.
57. de Haan T.R., van den Akker E.S., Porcelijn L., Oepkes D., Kroes A.C., Walther F.J. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008, 115:76-81. 10.1111/j.1471-0528.2007.01555.x.
58. Dembinski J., Haverkamp F., Maara H., Hansmann M., Eis-Hubinger A.M., Bartmann P. Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops. BJOG 2002, 109:1232-1234.
59. Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ 1995, 311:1549-1552.
60. Metzman R., Anand A., DeGiulio P.A., Knisely A.S. Hepatic disease associated with intrauterine parvovirus B19 infection in a newborn premature infant. J Pediatr Gastroenterol Nutr 1989, 9:112-114.
61. Yoto Y., Kudoh T., Asanuma H., Numazaki K., Tsutsumi Y., Nakata S., et al. Transient disturbance of consciousness and hepatic dysfunction associated with human parvovirus B19 infection. Lancet 1994, 344:624-625.
62. Porter H.J., Quantrill A.M., Fleming K.A. B19 parvovirus infection of myocardial cells. Lancet 1988, 1:535-536.
63. Ryan G., Kelly E.N., Inwood S., Altman D., Seaward P.G.R., McParland P., et al. Long-term pediatric follow-up in non-immune hydrops secondary to parvovirus infection. Am J Obstet Gynecol 1997, 176(1 Part 2):S86.
64. Nagel H.T., de Haan T.R., Vandenbussche F.P., Oepkes D., Walther F.J. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007, 109:42-47. 10.1097/01. AOG.0000249611.67873.94.
65. von Kaisenberg C.S., Bender G., Scheewe J., Hirt S.W., Lange M., Stieh J., et al. A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation. Fetal Diagn Ther 2001, 16:427-432.
66. Wong S.F., Chan F.Y., Cincotta R.B., Tilse M. Human parvovirus B19 infection in pregnancy: should screening be offered to the low-risk population?. Aust N Z J Obstet Gynaecol. 2002, 42:347-351.
67. Crane J.M. Prenatal exposure to viral infections. Canadian J CME 1998, 10:61-74.
68. American College of Obstetrics and Gynecologists ACOG practice bulletin. Perinatal viral and parasitic infections. No 20, Sept 2000. Int J Gynaecol Obstet 2002, 76:95-107.
69. Health Protection Agency Rash Guidance Working Group Guidance on viral rash in pregnancy - investigation, diagnosis and management of viral rash illness, or exposure to viral rash illness, in pregnancy 2011, Health Protection Agency, London.
70. Cartter M.L., Farley T.A., Rosengren S., Quinn D.L., Gillespie S.M., Gary G.W., et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991, 163:282-285.
71. Crowcroft N.S., Roth C.E., Cohen B.J., Miller E. Guidance for control of parvovirus B19 infection in healthcare settings and the community. J Public Health Med. 1999, 21:439-446.
72. de Villemeur A.B., Gratacap-Cavallier B., Casey R., Baccard-Longère M., Goirand L., Seigneurin J.M., et al. Occupational risk for cytomegalovirus, but not for parvovirus B19 in child-care personnel in France. J Infect 2011, 63:457-467. 10.1016/j.jinf.2011.06.012.
73. Stelma F.F., Smismans A., Goossens V.J., Bruggeman C.A., Hoebe C.J. Occupational risk of human cytomegalovirus and parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence. Eur J Clin Microbiol Infect Dis 2009, 28:393-397. 10.1007/s10096-008-0635-y.
74. Katz V.L., Chescheir N.C., Bethea M. Hydrops fetalis from B19 parvovirus infection. J Perinatol 1990, 10:366-368.
75. Borna S., Mirzaie F., Hanthoush-Zadeh S., Khazardoost S., Rahimi-Sharbaf F. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops. J Clin Ultrasound 2009, 37:385-388. 10.1002/jcu.20613.
76. Cosmi E., Mari G., Delle Chiaie L., Detti L., Akiyama M., Murphy J., et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol 2002, 187:1290-1293.
77. Delle Chiaie L., Buck G., Grab D., Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol 2001, 18:232-236. 10.1046/j.0960-7692.2001.00540.x.
78. Mari G., Deter R.L., Carpenter R.L., Rahman F., Zimmerman R., Moise K.J., et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000, 342:9-14. 10.1056/NEJM200001063420102.
79. Chauvet A., Dewilde A., Thomas D., Joriot S., Vaast P., Houfflin-Debarge V., et al. Ultrasound diagnosis, management and prognosis in a consecutive series of 27 cases of fetal hydrops following maternal parvovirus B19 infection. Fetal Diagn Ther 2011, 30:41-47. 10.1159/000323821;10.1159/000323821.
80. von Kaisenberg C.S., Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001, 18:280-288. 10.1046/j.1469-0705.2001.00471.x.
81. Barrett J., Ryan G., Morrow R., Farine D., Kelly E., Mahony J. Human parvovirus B19 during pregnancy. J Soc Obstet Gynaecol Can 1994, 16:1253-1258.
82. Pryde P.G., Nugent C.E., Pridjian G., Barr M., Faix R.G. Spontaneous resolution of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Obstet Gynecol 1992, 79(5 Pt 2):859-861.
83. Carrington D., Gilmore D.H., Whittle M.J., Aitken D., Gibson A.A., Patrick W.J., et al. Maternal serum alpha-fetoprotein-a marker of fetal aplastic crisis during intrauterine human parvovirus infection. Lancet. 1987, 1:433-435.
84. Bernstein I.M., Capeless E.L. Elevated maternal serum alpha-fetoprotein and hydrops fetalis in association with fetal parvovirus B-19 infection. Obstet Gynecol 1989, 74(3 Pt 2):456-457.
85. Johnson D.R., Fisher R.A., Helwick J.J., Murray D.L., Patterson M.J., Downes F.P. Screening maternal serum alpha-fetoprotein levels and human parvovirus antibodies. Prenat Diagn 1994, 14:455-458.
86. Fairley C.K., Smoleniec J.S., Caul O.E., Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995, 346:1335-1337.
87. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G., Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208.